Published in Transfusion on January 01, 2006
Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood (2008) 2.43
Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One (2010) 1.33
Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011. Transfusion (2012) 1.27
Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy. Blood (2009) 0.92
A report of disseminated adenocarcinoma presenting as thrombotic thrombocytopenic purpura. Hematol Rep (2011) 0.89
AAV-mediated expression of an ADAMTS13 variant prevents shigatoxin-induced thrombotic thrombocytopenic purpura. Blood (2013) 0.87
Pathogenesis and prognosis of thrombotic microangiopathy. Clin Exp Nephrol (2007) 0.84
Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura. Am J Hematol (2008) 0.80
Recurrent thrombotic thrombocytopenic purpura-like syndrome as a paraneoplastic phenomenon in malignant peritoneal mesothelioma: a case report and review of the literature. Case Rep Oncol Med (2012) 0.78
Thrombotic thrombocytopenic purpura - analysis of clinical features, laboratory characteristics and therapeutic outcome of 24 patients treated at a Tertiary Care Center in Saudi Arabia. Pak J Med Sci (2017) 0.75
Opana-induced thrombotic microangiopathy masquerading as thrombotic thrombocytopenic purpura. Oxf Med Case Reports (2017) 0.75
Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med (2009) 5.48
Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med (2010) 5.23
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med (2006) 4.07
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet (2008) 3.74
Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood (2009) 3.18
Clinical utility of D-dimer in patients with suspected pulmonary embolism and nondiagnostic lung scans or negative CT findings. Chest (2004) 2.30
Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood (2008) 2.17
Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program (2004) 1.94
Parental communication and youth sexual behaviour. J Adolesc (2006) 1.87
Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports. Haematologica (2007) 1.87
Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion (2004) 1.84
The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. Am J Hematol (2010) 1.83
Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. Blood (2010) 1.76
Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review. Ann Intern Med (2004) 1.69
Corticosteroid side-effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives. Eur J Haematol (2009) 1.56
Drug-induced thrombocytopenia: an updated systematic review, 2008. Drug Saf (2009) 1.52
Complete recovery from refractory immune thrombocytopenic purpura in three patients treated with etanercept. Am J Hematol (2003) 1.50
Youth-parent communication and youth sexual behavior: implications for physicians. Fam Med (2006) 1.50
Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura. Blood (2014) 1.47
Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: A report of 10 patients and a systematic review of published cases. Oncologist (2007) 1.45
Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica (2007) 1.39
Management of immune thrombocytopenia--something old, something new. N Engl J Med (2010) 1.39
The prevalence, predictors, and consequences of peripheral sensory neuropathy in older patients. J Am Board Fam Pract (2004) 1.34
Relationships among youth assets and neighborhood and community resources. Health Educ Behav (2005) 1.28
Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011. Transfusion (2012) 1.27
Syndromes of thrombotic microangiopathy. N Engl J Med (2014) 1.25
Approach to the diagnosis and management of drug-induced immune thrombocytopenia. Transfus Med Rev (2013) 1.20
Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review. Transfusion (2007) 1.19
Recurrent acute thrombocytopenia in the hospitalized patient: sepsis, DIC, HIT, or antibiotic-induced thrombocytopenia. Am J Hematol (2010) 1.18
Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features. Pediatr Blood Cancer (2013) 1.16
Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood (2013) 1.13
Reliability and validity of the youth asset survey (YAS). J Adolesc Health (2002) 1.12
Systemic infections mimicking thrombotic thrombocytopenic purpura. Am J Hematol (2011) 1.10
The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol (2004) 1.09
Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion (2009) 1.09
Thrombocytopenia as an adverse effect of complementary and alternative medicines, herbal remedies, nutritional supplements, foods, and beverages. Eur J Haematol (2010) 1.08
Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw-Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients. Br J Haematol (2008) 1.03
Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor-cleaving protease activity. Blood (2002) 1.00
Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity. Br J Haematol (2007) 1.00
Overlapping features of thrombotic thrombocytopenic purpura and systemic lupus erythematosus. South Med J (2007) 1.00
Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. Haematologica (2011) 0.99
Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion (2004) 0.98
A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. Health Qual Life Outcomes (2007) 0.98
Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol (2008) 0.97
Adolescent tobacco use: the protective effects of developmental assets. Am J Health Promot (2002) 0.96
Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective. Health Qual Life Outcomes (2008) 0.95
Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2006) 0.95
An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Br J Haematol (2006) 0.94
Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apher (2006) 0.93
Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care. Am J Hematol (2003) 0.93
Fatigue in adult patients with primary immune thrombocytopenia. Eur J Haematol (2011) 0.93
Thrombotic thrombocytopenic purpura: 2008 update. Cleve Clin J Med (2008) 0.92
Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes. Am J Hematol (2010) 0.92
The association between multiple youth assets and sexual behavior. Am J Health Promot (2004) 0.92
Cognitive deficits after recovery from thrombotic thrombocytopenic purpura. Transfusion (2009) 0.92
Should all adult patients with diarrhoea-associated HUS receive plasma exchange? Lancet (2012) 0.91
Frequency and significance of HIV infection among patients diagnosed with thrombotic thrombocytopenic purpura. Clin Infect Dis (2009) 0.91